Literature DB >> 8559387

Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin.

R Voltz1, F V Rosen, T Yousry, J Beck, R Hohlfeld.   

Abstract

We report a patient with a reversible multifocal encephalopathy that developed 3 days after completion of treatment with intravenous immunoglobulin for Guillain-Barré syndrome. Magnetic resonance imaging showed reversible bioccipital white matter changes, and transcranial Doppler demonstrated transiently increased flow rates in all major cerebral arteries. We conclude that intravenous immunoglobulin therapy caused cerebral arterial vasospasm and a reversible encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8559387     DOI: 10.1212/wnl.46.1.250

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Ischemic stroke in pediatric moyamoya disease associated with immune thrombocytopenia--a case report.

Authors:  Tomohide Hayashi; Naoki Akioka; Daina Kashiwazaki; Naoya Kuwayama; Satoshi Kuroda
Journal:  Childs Nerv Syst       Date:  2015-02-08       Impact factor: 1.475

Review 2.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  Acute encephalopathy associated with intravenous immunoglobulin therapy.

Authors:  Akihiko Wada; Rika Yoshida; Kazushige Oda; Eiji Fukuba; Nobue Uchida; Hajime Kitagaki
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

Review 5.  Headache and Pain in Guillain-Barré Syndrome.

Authors:  Constantine Farmakidis; Seniha Inan; Mark Milstein; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2015-08

6.  Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy.

Authors:  A Ozkan; B Hakyemez; F Ozkalemkas; R Ali; V Ozkocaman; T Ozcelik; O Taskapilioglu; Y Altundal; A Tunali
Journal:  Neuroradiology       Date:  2006-09-16       Impact factor: 2.804

7.  Commentary.

Authors:  Govind Chavada; Hugh J Willison
Journal:  J Neurosci Rural Pract       Date:  2014-01

Review 8.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Case-control study of thromboembolic events associated with IV immunoglobulin.

Authors:  James B Caress; Lisa Hobson-Webb; Leah V Passmore; Anne P Finkbiner; Michael S Cartwright
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 10.  Intravenous immunoglobulin in lupus panniculitis.

Authors:  João Espírito Santo; M F Gomes; M J Gomes; L Peixoto; S C Pereira; A Acabado; J Freitas; G Vinhas de Sousa
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.